IDEXX Laboratories Announces First Quart...(ing statements as defined in the Private...),Health

Date:4/24/2009

ing statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations. Factors that could cause or contribute to such differences include the following: the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; the impact of a weak economy on demand for the Company's products and services; the impact of changes and disruptions in financial and currency markets; the effectiveness of the Company's sales and marketing activities; disruptions, shortages or pricing changes that affect the Company's purchases of products and materials from third parties, including from sole source suppliers; the Company's ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition, technological change, and veterinary hospital consolidation on the markets for the Company's products; the Company's ability to manufacture complex biologic products; the effect of government regulation on the Company's business, including government decisions about whether and when to approve the Company's products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of the Company's products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; the Company's ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; the effe
'/>"/>

SOURCE IDEXX Laboratories, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. IDEXX Laboratories to Present at JPMorgan Healthcare Conference
2. IDEXX Laboratories to Release 2007 Fourth Quarter and Full-Year Financial Results
3. IDEXX Laboratories Announces Fourth Quarter Results
4. IDEXX Laboratories Announces Increase in Share Repurchase Program
5. IDEXX Laboratories to Release 2008 First Quarter Financial Results
6. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
7. IDEXX Laboratories Names William Brown Corporate Vice President
8. IDEXX Laboratories to Release 2008 Fourth Quarter and Full-Year Financial Results
9. IDEXX Laboratories Announces Fourth Quarter and Full Year Results
10. IDEXX Laboratories to Release 2009 First Quarter Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)